Generated: April 26, 2017
|Title:||Aqueous risperidone formulations|
|Abstract:||The present invention is concerned with physicochemically stable aqueous solutions of risperidone for oral and parenteral administration; processes for preparing such formulations.|
|Inventor(s):||Francois; Marc Karel Jozef (Beerse, BE), Dries; Willy Maria Albert Carlo (Beerse, BE)|
1. An aqueous solution suitable for oral and parenteral administration comprising water, risperidone or a pharmaceutically acceptable acid addition salt thereof, characterized in that
said solution comprises a buffer to maintain the pH in the range of 2 to 6 and is essentially free of sorbitol.
2. A solution according to claim 1 wherein said pH range is obtained with a tartaric acid/sodium hydroxide buffer.
3. A solution according to claim 1 wherein the amount of risperidone ranges from 0.01% to 1% by weight based on the total volume of the solution.
4. A solution according to claim 1 having a pH ranging from 3 to 4 which is suitable for oral administration.
5. A solution according to claim 4 further comprising benzoic acid as a preservative.
6. A solution according to claim 5 containing (a) 1 mg/ml risperidone; (b) 2 mg/ml benzoic acid; (c) 7.5 mg/ml tartaric acid and sufficient sodium hydroxide to adjust the pH in the range from 3 to 4; and (d) water q.s. ad 1 ml.
7. A solution according to claim 6 further comprising one or more members selected from the group consisting of sweetening agents and flavouring substances.
8. A solution according to claim 1 having a pH ranging from 5 to 6 which is suitable for parenteral administration.
9. A solution according to claim 4 further comprising sodium chloride as an isotonizing agent.
10. A solution according to claim 9 containing (a) 1 mg/ml risperidone; (b) 5 mg/ml sodium chloride; (c) 7.5 mg/ml tartaric acid and sufficient sodium hydroxide to adjust the pH in the range from 5 to 6; and (d) water q.s. ad 1 ml.
11. A process of preparing a solution according to claim 1 comprising the steps of (a) adding the acid component of the buffer and the active ingredient risperidone to an amount of water, (b) stirring the mixture until complete dissolution and cooling the solution to room temperature, (c) adjusting the pH with the base component of the buffer, and (d) further diluting the solution with water to the required end-volume.
12. A process according to claim 11 for preparing an oral solution as defined in claim 5 wherein step (a) is preceded by the steps of: (a) dissolving the preservative in an amount of heated water, and (b) diluting the solution with about an equal amount of water.
13. A process according to claim 11 for preparing an parenteral solution as defined in claim 9 wherein step (d) is preceded immediately by the step of rendering the solution about isotonic by the addition of an appropriate amount of isotonizing agent, and is followed by autoclaving.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.